Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Pulmonary Arterial Hypertension
IRCT20120520009801N18Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in pulmonary arterial hypertension (PAH), sponsored by Mashhad University of Medical Sciences. Started Sep 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on IRCT20120520009801N18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120520009801N18.